The peptide behind Ozempic and Wegovy. A GLP-1 receptor agonist that revolutionized weight management and diabetes treatment with robust clinical evidence.

A groundbreaking dual-incretin peptide developed by Eli Lilly, FDA-approved for type 2 diabetes (Mounjaro) and obesity (Zepbound). Shows the strongest weight loss results of any peptide to date.

FDA-approved for HIV-associated lipodystrophy. The only GHRH analog with FDA approval, known for reducing visceral fat and improving body composition with a favorable safety profile.

Eli Lilly's next-generation obesity peptide — the world's first triple-incretin agonist. Phase II trials showed up to 24.2% weight loss at 48 weeks, potentially surpassing tirzepatide.

Boehringer Ingelheim's dual-agonist peptide showing exceptional results for both weight loss and liver fat reduction. Unique glucagon component targets hepatic steatosis directly.

A modified GH fragment designed to retain fat-burning properties while avoiding the metabolic risks of full growth hormone. Studied for obesity and cartilage repair.

A mitochondria-derived peptide discovered in 2015 that functions as an exercise mimetic. Improves metabolic homeostasis, insulin sensitivity, and exercise capacity.